Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Investing Activities: 2011-2024

Historic Cash from Investing Activities for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to -$8.6 million.

  • Adma Biologics' Cash from Investing Activities fell 1208.56% to -$14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.4 million, marking a year-over-year decrease of 236.91%. This contributed to the annual value of -$8.6 million for FY2024, which is 72.15% down from last year.
  • As of FY2024, Adma Biologics' Cash from Investing Activities stood at -$8.6 million, which was down 72.15% from -$5.0 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Cash from Investing Activities registered a high of -$5.0 million during FY2023, and its lowest value of -$13.9 million during FY2022.
  • Over the past 3 years, Adma Biologics' median Cash from Investing Activities value was -$8.6 million (recorded in 2024), while the average stood at -$9.2 million.
  • In the last 5 years, Adma Biologics' Cash from Investing Activities soared by 64.19% in 2023 and then crashed by 72.15% in 2024.
  • Adma Biologics' Cash from Investing Activities (Yearly) stood at -$12.7 million in 2020, then declined by 6.18% to -$13.5 million in 2021, then decreased by 2.96% to -$13.9 million in 2022, then spiked by 64.19% to -$5.0 million in 2023, then crashed by 72.15% to -$8.6 million in 2024.